Efek Remdesivir pada Pasien Covid-19
Abstract
Pandemi global penyakit Novel Coronavirus 2019 telah menciptakan kebutuhan mendesak antivirus yang efektif, salah satu antivirus yang digunakan adalah Remdesivir. Tujuan penelitian menilai kualitas artikel secara kualitatif yang menyajikan hasil uji klinis acak tentang efektifitas dan keamanan Remdesivir pada pasien COVID-19. Systematic review ini dilakukan berdasarkan Item Pelaporan Pilihan untuk Tinjauan Sistematis dan Meta Analisis. Pencarian basis data sistematis dilakukan dari bulan Desember 2020 - Februari 2021. Database yang digunakan antara lain: Google Scholar, Pubmed, dan NIH. Penulis menilai kualitas studi RCT dengan menggunakan standar GRADE. Kata kunci yang digunakan antara lain: “COVID-19 and Remdesivir”, “COVID-19 and remdesivir and randomized controlled trial”, dan “remdesivir and randomized controlled trial”. Pasien yang diberikan Remdesivir mempunyai waktu yang lebih cepat untuk perbaikan klinis dibandingkan dengan plasebo dengan durasi gejala hingga 10 hari atau kurang, hasil lain menunjukan waktu pemulihan rata-rata 9 hari. Efek samping yang dicatat selama penelitian berada pada tingkat keparahan 1 atau 2. Seluruh bukti klinis melaporkan efek samping yang berada pada grade 2 dan masih dinyatakan aman.
References
Beigel, J. H. et al. (2020) ‘Remdesivir for the Treatment of Covid-19 — Final Report’, New England Journal of Medicine, 383(19), pp. 1813–1826. doi: 10.1056/nejmoa2007764.
Contini, C. et al. (2020).The novel zoonotic COVID-19 pandemic: an expected global health concern. J. Infect. Dev. Ctries. 14, 254–264.
DeWit, E. et al. (2020) ‘Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection’, Proceedings of the National Academy of Sciences of the United States of America. doi: 10.1073/pnas.1922083117.
Goldman, J. D. et al. (2020) ‘Remdesivir for 5 or 10 Days in Patients with Severe Covid-19’, New England Journal of Medicine, 383(19), pp. 1827–1837. doi: 10.1056/nejmoa2015301.
Handayani, R. T., Arradini, D., Darmayanti, A. T., Widiyanto, A., & Atmojo, J. T. (2020). Pandemic Covid-19, Body Immunity Response, and Herd Immunity. Jurnal Ilmiah Permas: Jurnal Ilmiah STIKES Kendal, 10(3), 373-380.
Horby, P. et al. (2020) ‘Dexamethasone for COVID-19-Preliminary Report Effect of Dexamethasone in Hospitalized Patients with COVID-19-Preliminary Report RECOVERY Collaborative Group*’, medRxiv.
Humeniuk, R. et al. (2020) ‘Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID-19, in Healthy Subjects’, Clinical and Translational Science, 13(5), pp. 896–906. doi: 10.1111/cts.12840.
Jorgensen, S. C. J., Kebriaei, R. and Dresser, L. D. (2020) ‘Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19’, Pharmacotherapy, 40(7), pp. 659–671. doi: 10.1002/phar.2429.
Moher, D. et al. (2015) ‘Preferred reporting items for systematic review and meta-analysis protocols ( PRISMA-P ) 2015 statement’, pp. 1–9.
Sanders, J. M. et al. (2020) ‘Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review’, JAMA - Journal of the American Medical Association. doi: 10.1001/jama.2020.6019.
Pruijssers, A.et al.Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice.
Spinner, C. D. et al. (2020) ‘Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19: A Randomized Clinical Trial’, JAMA - Journal of the American Medical Association, 324(11), pp. 1048–1057. doi: 10.1001/jama.2020.16349.
Sheahan, T.P. et al. (2017). Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci. Transl. Med. 9, 396.
Wang, M. et al. (2020) ‘Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro’, Cell Research. doi: 10.1038/s41422-020-0282-0.
Williamson, B. N. et al. (2020) ‘Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2’, Nature. doi: 10.1038/s41586-020-2423-5.
World Health Organization (2020) ‘Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected’, Who.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
